Literature DB >> 15985005

Differentially expressed cellular genes following HBV: potential targets of anti-HBV drugs?

J Yang1, X C Bo, J Yao, N M Yang, S Q Wang.   

Abstract

The aim of the study was to screen for cellular genes that are differentially expressed following hepatitis B virus (HBV) infection, in an attempt to identify potential targets of anti-HBV drugs. An oligonucleotide microarray containing 231 virus-infection-associated genes was prepared. Differential gene expression in HepG2.2.15 cells compared to control with HepG2 cells was analysed by this in-house microarray. The change in gene expression in HepG2.2.15 cells treated by lamivudine on days 4 and 8 after exposure was also studied. Semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) was used to comfirm the differentially expressed genes induced by HBV and lamivudine. There were 31 upregulated and four downregulated genes in HepG2.2.15 cells compared with the HepG2 control cells. Eleven genes were consistently altered by lamivudine at both time points. Of the 31 genes that were upregulated in HepG2.2.15 cells, there were seven genes which were downregulated by lamivudine. Of the four downregulated genes, there was one gene which was upregulated by lamivudine. Of the differentially expressed genes induced by HBV and lamivudine, the expression of five genes was confirmed by semi-quantitative RT-PCR. These results shed new light on the effects of HBV and lamivudine on cellular gene expression. Differentially expressed genes induced by HBV and lamivudine could potentially become new anti-HBV drug targets in novel therapies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15985005     DOI: 10.1111/j.1365-2893.2005.00611.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  4 in total

1.  Telbivudine treatment corrects HBV-induced epigenetic alterations in liver cells of patients with chronic hepatitis B.

Authors:  Yi Tian; Dongjing Ni; Weibing Yang; Yi Zhang; Keji Zhao; Jianxun Song; Qing Mao; Zhiqiang Tian; Jennifer C van Velkinburgh; Di Yang; Yuzhang Wu; Bing Ni
Journal:  Carcinogenesis       Date:  2013-09-25       Impact factor: 4.944

Review 2.  Drugs in Development for Hepatitis B.

Authors:  Altaf Dawood; Syed Abdul Basit; Mahendran Jayaraj; Robert G Gish
Journal:  Drugs       Date:  2017-08       Impact factor: 9.546

3.  An earthworm protease cleaving serum fibronectin and decreasing HBeAg in HepG2.2.15 cells.

Authors:  Xue-Qing Wang; Lan Chen; Rong Pan; Jing Zhao; Ying Liu; Rong-Qiao He
Journal:  BMC Biochem       Date:  2008-11-24       Impact factor: 4.059

4.  Effects of lamivudine on serum albumin levels correlate with pretreatment HBV-DNA levels in cirrhotic patients.

Authors:  Makoto Nakamuta; Kazuhiro Kotoh; Munechika Enjoji; Eiji Kajiwara; Junya Shimono; Akihide Masumoto; Toshihiro Maruyama; Norihiro Furusyo; Hideyuki Nomura; Hironori Sakai; Kazuhiro Takahashi; Koichi Azuma; Shinji Shimoda; Yuichi Tanabe; Jun Hayashi
Journal:  Comp Hepatol       Date:  2007-05-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.